PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Construing the claims to include technical effects mentioned in the description (T 1924/20)

  • Sector: Biotechnology
  • 8th May 2023
When it comes to interpreting patent claims, the European Patent Office is sending mixed signals. A new decision, T 1924/20, adds fuel to the fire, making a referral to the Enlarged Board of Appeal more necessary than ever.
 

Originally published on IPKat.

Claim interpretation is the current hot-topic at the EPO, specifically the extent to which the description should be taken into account in claim interpretation. The EPO has recently taken a hard line against using the description to narrow the meaning of clear language in the claims. There is, however, another line of recent EPO case law which has taken a similarly hard line on requiring the description to be amended in line with the claims. According to these Board of Appeal decisions, inconsistencies between the claims and the description would confuse the skilled person over how to interpret the claim language. To this Kat, these lines of case law are incompatible: either clear language in the claims should be interpreted in view of the description, or it should not, the EPO cannot have it both ways. To complicate things further, there is also mounting Boards of Appeal case law finding the contrary position on description amendments, i.e. that the description does not have to be amended in line with the claims. 

It is thus becoming increasingly clear that a referral to the Enlarged Board of Appeal on claim interpretation is necessary to harmonise Boards of Appeal case law. In this context, the recently published Board of Appeal decision in T 1924/20 adds further weight to the line of Boards of Appeal case law that the description is irrelevant to the interpretation of otherwise clear claim language.

Construing the claims to incorporate a functional effect from the description

The decision in T 1924/20 is interesting for its rejection of an approach to claim interpretation whereby functional effects mentioned in the description may be incorporated into the claims via judicious construction of the claim language. The patent in question (EP2898704) related to a hearing aid that could be worn for several months or years without being taken out, and a method of manufacturing hearing aids. The problem to be solved by an “extended wear” hearing aid of this type was how to protect the hearing aid’s electronics from prolonged exposure to ear fluids. The patent was opposed for lack of inventive step.

The Patentee’s defence relied upon a claim construction based on the description of the patent. The granted claim specified a method of manufacturing a hearing aid comprising encapsulating the electronic module. The Patentee argued that this encapsulating step would necessarily lead to a reduction in the chance of moisture reaching the electronics of the device, and that the prior art did not disclose such a step. In support of their claim interpretation the Patentee pointed to passages in the description of the patent stating that the position of the electronics module in the hull of the device “reduced the chance of moisture breaching the capsulation”. 

The Board of Appeal was not convinced by the Patentee’s arguments. The Board of Appeal argued that the passages of the description cited by the Patentee could not change the interpretation of the claim Particularly, the Board of Appeal dismissed an approach to claim interpretation that incorporated limitations from the description, finding that ‘a skilled reader of a patent claim would, for many reasons, interpret the claims based essentially on their own merits […] This is because the “subject-matter of the European patent” (cf. Article 100(a) EPC) is defined by the claims and only by them’. 

The Board of Appeal also cited with approval the reasoning from the Boeing catastrophic comma loss case (T 1127/16). In Boeing, the Board of Appeal found that it was not possible for the patentee to have recourse to the description in order to overcome an added matter objection resulting from the loss of a single comma from the claims. The Board of Appeal particularly found in Boeing that the description could not be used to change the meaning of otherwise clear language in the claims. The Board of Appeal in the present case agreed with this reasoning, finding that “when interpreting the claims, the description and drawings cannot be relied on as a sort of fall-back or supplementary-guidance tool for filling up gaps or for resolving inconsistencies in a claim to the patent proprietor’s advantage”. 

The appeal was therefore set aside and the patent revoked. Interestingly, the Patentee did not seek to rescue the patent by incorporating the functional limitation into the claims. 

Analysis

T 1924/20 is yet another Board of Appeal decision to add to the pile of recent case law finding against a role for the description in claim interpretation (see also T 0821/20). In all of these cases, the decisions have gone against Patentees arguing for a different interpretation of the claims based on the description in order to overcome an added matter or inventive step objection. The EPO has thus taken a hard line against the particular use of the description to narrow the meaning of the claim language. It will be interesting to see whether in infringement actions, a similarly hard line will be taken against the attempts of alleged infringers to narrow the claims in arguments of non-infringement. 

Related insights...

G 1/25 (description amendments) amicus curiae: The battle lines are drawn

  • 4th March 2026
If you want to start an argument amongst European patent attorneys, just mention description amendments. As the comments on this and other blogs attest, adaptation of the description is a highly divisive issue and the debate can get decidedly heated (with our US colleagues looking on with bemusement).

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic invention.

Non-reproducible products can be the closest prior art (T 1719/21)

  • 17th February 2026
G 1/23 establishes that products made available to the public are prior art in Europe, regardless of reproducibility. While this simplifies novelty, focusing strictly on disclosure dates, it complicates inventive step assessments. Notably, T 1719/21 questions whether these non-reproducible products can serve as the “closest prior art” in the EPO’s problem-solution approach.

ViCo oral proceedings: Whatever happened to the in-person “Gold-Standard”?

  • 14th December 2025
We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21? 

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector field is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025 (see Evolve Insights), we review the most impactful decisions of the year relating to clinical-stage inventions. 

EPO pharma case law trends 2025: Antibodies and biologics

  • 19th November 2025
The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted design and in silico modelling. Patent law must respond to these new challenges. What better time to take a look at the trends from the EPO case…

Insufficiency resulting from mutually exclusive definitions: The repercussive effect of dependent claims (T 0878/23)

  • 18th November 2025
In T 0878/23, the Board of Appeal ruled that mutually exclusive ranges in dependent claims constitute fatal insufficiency rather than a mere lack of clarity. This decision underscores the “repercussive effect” of claim dependencies, warning that internal contradictions can make an invention technically impossible to perform.

First use of G 1/24 to broaden clear claim language (T 1849/23)

  • 16th November 2025
This significant decision is the first from the Boards of Appeal to apply G 1/24 to the use of information from the description to broaden otherwise clear claim language.

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us